Clinical Trial Update: Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy in MSI-H/dMMR locally advanced gastric or gastr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING